• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 03 2025

Malin Otmani

-

September 16, 2025

Share article on X
Share article on Linkedin

Published: September 16, 2025

Top stories

MedTech Business – August 26, 2026

Nexstim’s latest brain-mapping system ordered by long-time European hospital customer

Finnish medtech company Nexstim has received an order for its latest-generation NBS 6 navigated brain stimulation system from an existing hospital customer in Europe, as the customer upgrades from an earlier-generation platform.

MedTech Business – August 26, 2026

Revenio’s iCare DRSplus powers first FDA-cleared AI screening tool for diabetic retinopathy

Finnish ophthalmic device maker Revenio’s iCare DRSplus fundus camera is now part of the first FDA-cleared AI-based diabetic retinopathy screening solution to reach the US market, through a partnership with health-tech company iHealthScreen.

Clinical Trials – August 26, 2026

BioInvent’s preclinical data published in Cancer Research

Swedish biotech BioInvent has published preclinical data on its two anti-TNFR2 antibodies, BI-1808 and BI-1910, in the journal Cancer Research, showing the two candidates drive anti-tumour immunity through distinct mechanisms – including in tumour types that typically resist checkpoint inhibitor therapy.

Biotech Business – August 26, 2026

Bio-Works secures new US customer

Bio-Works Technologies has signed a new US customer, a major American biotech company, as a collaboration partner in the development of a new drug. The order is valued at SEK 2.8 million.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

MedTech Business - August 26, 2026

Nexstim’s latest brain-mapping system ordered by long-time European hospital customer

Finnish medtech company Nexstim has received an order for its latest-generation NBS 6 navigated brain stimulation system from an existing hospital customer in Europe, as the customer upgrades from an earlier-generation platform.

MedTech Business - August 26, 2026

Revenio’s iCare DRSplus powers first FDA-cleared AI screening tool for diabetic retinopathy

Finnish ophthalmic device maker Revenio's iCare DRSplus fundus camera is now part of the first FDA-cleared AI-based diabetic retinopathy screening solution to reach the US market, through a partnership with health-tech company iHealthScreen.

Clinical Trials - August 26, 2026

BioInvent’s preclinical data published in Cancer Research

Swedish biotech BioInvent has published preclinical data on its two anti-TNFR2 antibodies, BI-1808 and BI-1910, in the journal Cancer Research, showing the two candidates drive anti-tumour immunity through distinct mechanisms – including in tumour types that typically resist checkpoint inhibitor therapy.

Biotech Business - August 26, 2026

Bio-Works secures new US customer

Bio-Works Technologies has signed a new US customer, a major American biotech company, as a collaboration partner in the development of a new drug. The order is valued at SEK 2.8 million.

Collaboration - August 26, 2026

Koite Health and Brånemark Osseointegration Centers launch research partnership

Finnish medtech company Koite Health has entered a research collaboration with Associated Brånemark Osseointegration Centers (ABOC), the global implantology network built on Professor Per-Ingvar Brånemark's osseointegration research, to study how at-home antibacterial care can be integrated into structured preventive protocols for dental implant patients.

Business article - August 25, 2026

Q&A: Simon Fredriksson, CEO and Co-founder, Pixelgen

NLS asked the CEO and co-founder of Pixelgen about entrepreneurship in Sweden, the company's global commercialization strategy and the most exciting clinical applications of the company's Proxiome kit.

Science News - August 25, 2026

Turku researchers uncover molecular mechanism behind aggressive colorectal cancer

Researchers at the University of Turku, working with France's Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.